Filing Flows › Comparisons › TVTX vs COLL
Travere Therapeutics vs Collegium Pharmaceutical: TVTX and COLL compared
Travere Therapeutics is the larger company: $225M of revenue in its latest quarter (Q3 2026) against $216M for Collegium Pharmaceutical (Q3 2026). Travere Therapeutics is growing faster (+36% against +3% a year earlier). Collegium Pharmaceutical is more profitable, with an operating margin of 13.3% against -30.3%.
Where the money goes: TVTX and COLL
Travere Therapeutics (TVTX) · Q3 2026
Travere Therapeutics, Q3 2026: revenue $225M (+36% year over year), operating margin -30.3%, net loss $52.3M, operating cash flow $98.2M. The chart follows the revenue to costs, profit and cash.
Collegium Pharmaceutical (COLL) · Q3 2026
Collegium Pharmaceutical, Q3 2026: revenue $216M (+3% year over year), operating margin 13.3%, net earnings $21.8M, operating cash flow $86.5M. The chart follows the revenue to costs, profit and cash.
| Travere Therapeutics (TVTX) | Collegium Pharmaceutical (COLL) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $225M | $216M |
| Revenue growth, Y/Y | +36% | +3% |
| Gross margin | — | 58.0% |
| Operating margin | -30.3% | 13.3% |
| Net earnings | −$52.3M | $21.8M |
| Net margin | -23.3% | 10.1% |
| Operating cash flow | $98.2M | $86.5M |
| Free cash flow | — | $86.3M |
| Market value | — | $717M |
| P/E | — | 15.0× |
| Analysts’ mean target | — | $49.00 |
Where the revenue comes from
Travere Therapeutics
- Total net product sales: $220M (98%)
- License and collaboration revenue: $4.4M (2%)
Collegium Pharmaceutical
- Belbuca: $57.7M (27%)
- Jornay PM: $51.9M (24%)
- Xtampza ER: $45.8M (21%)
- Azstarys: $26.5M (12%)
Questions
Which is bigger, Travere Therapeutics or Collegium Pharmaceutical?
Travere Therapeutics is the larger company: $225M of revenue in its latest quarter (Q3 2026) against $216M for Collegium Pharmaceutical (Q3 2026).
Is Travere Therapeutics or Collegium Pharmaceutical growing faster?
Travere Therapeutics is growing faster (+36% against +3% a year earlier).
Which is more profitable, Travere Therapeutics or Collegium Pharmaceutical?
Collegium Pharmaceutical is more profitable, with an operating margin of 13.3% against -30.3%.
More: Travere Therapeutics earnings · how Travere Therapeutics makes money · Collegium Pharmaceutical earnings · how Collegium Pharmaceutical makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 2, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.